


PHARMACEUTICAL 2023

Calithera Biosciences Inc. Rank 321 of 446





CALITHERA



PHARMACEUTICAL 2023



Calithera Biosciences Inc. Rank 321 of 446

The relative strengths and weaknesses of Calithera Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Calithera Biosciences Inc. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Calithera Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is -25%, being 68% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	26,624
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,390
Liabilities, Non-Current	136
Other Assets	1,618
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	758
Other Net Income	2,424
Other Revenues	0
Property and Equipment	434
Research and Development	28,533
Selling, General and Administrative Expense	13,541

Output Variable	Value in 1000 USD
Assets	28,676
Liabilities	8,284
Expenses	42,074
Revenues	0
Stockholders Equity	20,392
Net Income	-39,650
Comprehensive Net Income	-39,650
Economic Capital Ratio	-25%

